Celldex Therapeutics, Inc. (CLDX) — SC 13G/A Filings
All SC 13G/A filings from Celldex Therapeutics, Inc.. Browse 10 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (10)
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 13, 2024
- SC 13G/A Filing — Nov 12, 2024
- SC 13G/A Filing — Nov 8, 2024
- SC 13G/A Filing — Feb 14, 2024
-
Vanguard Discloses 7.0% Stake in Celldex Therapeutics
— Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an updated SC 13G/A on February 13, 2024, disclosing its ownership in Celldex Therapeutics Inc. As of Decembe -
FMR LLC & Abigail Johnson Maintain 12.89% Stake in Celldex (CLDX)
— Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership stake in Celldex Therapeutics, Inc. (CLDX) to 12.891% as of Febr -
Wellington Management Discloses 6.02% Stake in Celldex Therapeutics
— Feb 8, 2024 Risk: low
Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 8, 2024, disclosing its ownership in Celldex Therapeutics, Inc. -
BlackRock Amends Celldex Therapeutics Stake, Holds Significant Position
— Jan 26, 2024
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Celldex Therapeutics, Inc. (CDLX) as of December 31, 2023. This filing
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX